Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

81.33USD
4:02pm EDT
Change (% chg)

$0.37 (+0.46%)
Prev Close
$80.96
Open
$80.96
Day's High
$81.60
Day's Low
$80.71
Volume
815,999
Avg. Vol
1,223,177
52-wk High
$86.71
52-wk Low
$64.25

LLY.N

Chart for LLY.N

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $89,327.57
Shares Outstanding(Mil.): 1,103.35
Dividend: 0.52
Yield (%): 2.57

Financials

  LLY.N Industry Sector
P/E (TTM): 39.32 29.39 30.30
EPS (TTM): 2.06 -- --
ROI: -- 13.71 13.24
ROE: -- 14.66 14.40

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

Apr 21 2017

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

April 21 A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

Apr 21 2017

Boehringer eyes marked sales gain, boosted by animal health

INGELHEIM, Germany, April 5 Boehringer Ingelheim, Germany's second-largest drugmaker, said on Wednesday it was targeting a marked gain in 2017 revenues, boosted by new animal health businesses it acquired from Sanofi.

Apr 05 2017

BRIEF-Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock

* Lilly Endowment Inc reports open market sale of 210,000 of co's common stock on march 30 at $84.674 per share - SEC filing Source text (http://bit.ly/2nrnkag) Further company coverage:

Mar 31 2017

BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

* Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

Mar 28 2017

BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln

* CEO John C. Lechleiter's 2016 total compensation was $18.4 million versus $16.6 million in 2015

Mar 20 2017

Federal Circuit revives Cialis patent claims against Lilly

By Jan Wolfe The U.S. Court of Appeals for the Federal Circuit has breathed new life into a research institute’s claims that Eli Lilly and Co’s erectile dysfunction drug Cialis infringes on one of its patents.

Feb 28 2017

Accera's Alzheimer's trial fails, in yet another setback for disease

Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease.

Feb 28 2017

Accera's Alzheimer's trial fails, in yet another setback for disease

Feb 28 Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease.

Feb 28 2017

AARP, Eli Lilly support Sanofi, Regeneron in cholesterol drug fight

Seniors' advocacy group AARP and drugmaker Eli Lilly & Co on Thursday urged a federal appeals court to overturn a court order barring sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent.

Feb 24 2017

More From Around the Web

Competitors

Earnings vs. Estimates